



INTERNATIONAL  
ATHEROSCLEROSIS  
SOCIETY

FONDAZIONE  
GIOVANNI LORENZINI  
MILAN, ITALY



GIOVANNI LORENZINI  
MEDICAL FOUNDATION  
HOUSTON, USA



# 1<sup>st</sup> International Course **INTEGRATED BIOMARKERS**

*Biochemical and Bioimaging Endpoints  
in Cardiocerebrovascular Diagnosis, Prevention, Therapy,  
and Drug Development*

Lugano (Switzerland), October 27-29, 2005



*Under the auspices of*  
**European Association of Nuclear Medicine  
Society of Atherosclerosis Imaging  
International Task Force of Prevention  
of Coronary Heart Disease**



WORLD HEART  
FEDERATION®



Fondazione italiana per il cuore

## CHAIRPERSONS

**O.J. Bjerrum** (Denmark) - **V. Fuster** (USA) - **R. Paoletti** (Italy)

Course Coordinator: **A.P. Peracino** (Italy)

## SCIENTIFIC PROGRAMME COMMITTEE

**A.L. Catapano** (Italy) - **F. Crea** (Italy) - **S.M. Marcovina** (USA) - **P.L. Pieri** (Italy) - **E. Tremoli** (Italy)

## INTERNATIONAL ADVISORY BOARD

**G. Assmann** (Germany) - **P. Bonini** (Italy) - **G. Brown** (USA) - **A.L. Catapano** (Italy) - **R.H. Christenson** (USA) - **F. Crea** (Italy) - **P. De Feyter** (The Netherlands) - **R. Dietz** (Germany) - **M. Ferrari** (Italy) - **J. Heinecke** (USA) - **D. Hochstrasser** (Switzerland) - **A. Jacobs** (Germany) - **P. Libby** (USA) - **S.M. Marcovina** (USA) - **A. Maseri** (Italy) - **P. Mocarelli** (Italy) - **M. Müller** (Austria) - **S.E. Nissen** (USA) - **D. Orloff** (USA) - **M. Panteghini** (Italy) - **M.S. Phillips** (Canada) - **P.L. Pieri** (Italy) - **M. Plebani** (Italy) - **P. Raggi** (USA) - **P. Ridker** (USA) - **G. Steiner** (Canada) - **J-C. Tardif** (Canada) - **E. Tremoli** (Italy) - **A. Von Eckardstein** (Switzerland)

## SCOPE OF THE COURSE

To verify and endorse the knowledge of and the experience in the combined use of the predictive value of integrated biochemical and bioimaging markers in the clinical decision making and in drug development in the cardiocerebrovascular diseases.

## TARGET AUDIENCE

Researchers, physicians, regulatory affairs officers, and scientists from imaging, diagnostic and pharmaceutical industries, who are interested in the use of integrated biomarkers to support decision-making and to improve patient assessment.

## PARTICIPANTS IN THE COURSE

It is expected an international attendance of 150 participants. In the workshops the attendees will be divided into two groups to facilitate more interactive discussion.

### SCIENTIFIC - ORGANIZING SECRETARIATS

Main Office  
**Biomarkers 2005**  
Fondazione Giovanni Lorenzini  
Medical Science Foundation  
Via A. Appiani 7  
20121 Milan, Italy  
Phone: (+39) 02 29006267  
Fax: (+39) 02 29007018  
E-mail: [biomarkers@lorenzinifoundation.org](mailto:biomarkers@lorenzinifoundation.org)

Branch Office  
**Biomarkers 2005**  
Giovanni Lorenzini  
Medical Foundation  
6535 Fannin, M.S. A-601  
Houston, Texas 77030 - 2704 (USA)  
Phone: (+1) 713 7970401  
Fax: (+1) 713 7968853  
E-mail: [biomarkers@bcm.tmc.edu](mailto:biomarkers@bcm.tmc.edu)

## SCIENTIFIC PROGRAMME

THURSDAY, OCTOBER 27

### Opening Remarks (2.00 p.m.)

**Ole J. Bjerrum** (Copenhagen, Denmark)  
**Valentin Fuster** (New York, USA)  
**Rodolfo Paoletti** (Milan, Italy)

### Opening Lecture

**Introduction to Integrated Biomarkers in Cardiovascular Diagnosis, Prevention, and Therapy**  
**Valentin Fuster** (New York, USA)

### Plenary Session

**CLINICIANS' DECISION MAKING IN CARDIOCEREBROVASCULAR DISEASES: open questions**

<b>Risk Stratification in Asymptomatic Subjects</b>	<b>Wolfgang Koenig</b> (Ulm, Germany)
<b>Acute Coronary Syndrome</b>	<b>Juan Carlos Kaski</b> (London, UK)
<b>Heart Failure</b>	<b>Claudio Rapezzi</b> (Bologna, Italy)
<b>Transient Ischemic Attack and Stroke</b>	<b>Jan Sobesky</b> (Cologne, Germany)
<b>Diabetes</b>	<b>Antonio Pontiroli</b> (Milan, Italy)

*Purpose of this session:*

*To highlight the problems and critical areas in clinical decision making in five clinical-pathological areas for an individualized diagnosis.*

### Rapporteurs (throughout the Course)

*Rapporteurs will participate in all the sessions and will collect critical points, shadow areas, issues for reflection, and proposals to be discussed in the final session (Saturday, October 29).*

*They are experts on biochemical/bioimaging markers and on clinical decision making:*

**Santica M. Marcovina** (Seattle, USA)  
**Filippo Crea** (Rome, Italy)  
**Jean Davignon** (Montreal, Canada)  
**Pier Luigi Pieri** (Cesena, Italy)

## FRIDAY, OCTOBER 28

### Workshops

*Participants, divided into two groups, will attend all the Workshops*

#### **BIOCHEMICAL MARKERS TOWARDS INTEGRATION: methodological criteria**

*To define the criteria for the integration of biochemical markers in terms of:*

<b>Quality Specifications</b>	<b>Mauro Panteghini</b> (Milan, Italy)
<b>Clinical Utility</b>	<b>Allan S. Jaffe</b> (Rochester, USA)
<b>Health Economy</b>	<b>Bengt Jönsson</b> (Stockholm, Sweden)

#### **BIOIMAGING MARKERS TOWARDS INTEGRATION: methodological criteria**

*To define the criteria for the integration of bioimaging markers in terms of:*

<b>Quality Specifications</b>	<b>Pasquale Perrone Filardi</b> (Naples, Italy)
<b>Clinical Utility</b>	<b>Paolo Raggi</b> (New Orleans, USA)
<b>Health Economy</b>	<b>Leslee Shaw</b> (Los Angeles, USA)

#### **BIOCHEMICAL MARKERS TOWARDS INTEGRATION: predictive value**

*To define the predictive value of selected biomarkers alone or in combination in terms of:*

<b>Acute Coronary Syndrome</b>	<b>Martin Möckel</b> (Berlin, Germany)
<b>Heart Failure</b>	<b>Ulf Landmesser</b> (Hannover, Germany)
<b>Transient Ischemic Attack and Stroke</b>	<b>Joan Montaner</b> (Barcelona, Spain)

#### **BIOIMAGING MARKERS TOWARDS INTEGRATION: predictive value**

*To define the predictive value of selected biomarkers alone or in combination in terms of:*

<b>Acute Coronary Syndrome</b>	<b>Jeanette Schulz-Menger</b> (Berlin, Germany)
<b>Heart Failure</b>	<b>Mauro Pepi</b> (Milan, Italy)
<b>Transient Ischemic Attack and Stroke</b>	<b>Gian Luigi Lenzi</b> (Rome, Italy)

## SATURDAY, OCTOBER 29

### Round Table

#### INTEGRATED BIOCHEMICAL AND BIOIMAGING MARKERS IN CARDIOCEREBROVASCULAR DISEASES:

#### *answers and proposals for further developments*

*To define the pros and cons of the use of integrated biomarkers in clinical decision making in:*

**Risk Stratification in Asymptomatic Subjects**

**Acute Coronary Syndrome**

**Heart Failure**

**Transient Ischemic Attack and Stroke**

**Diabetes**

*Discussants:*

**Rapporteurs and Clinicians**

*Purpose of this session:*

*This session will attempt to answer the questions presented in the opening plenary session. The rapporteurs will present a synthesis of the critical points, shadow areas, issues for reflection, and proposals to be discussed that emerged during the various Workshops. The rapporteurs and the clinicians will discuss the pros and cons of the use of integrated biomarkers in the clinical decision making process.*

### Round Table

#### REMARKS FROM THE STAKEHOLDERS

#### *Regulatory Agencies, Health Organizations, Scientists, Scientific Societies, and Industry*

*Chairpersons:* **Gerd Assmann** (Münster, Germany)

**Rodolfo Paoletti** (Milan, Italy)

*To define regulatory issues, health economy, and clinical trials needs in the area of diagnosis, prevention and treatment of cardiocerebrovascular diseases.*

*Discussants:*

**Scientists and representatives from regulatory agencies, health organizations, scientific societies, and industry**

*Purpose of this session:*

*The discussants will present their points of view and describe the unmet needs that may be more directly addressed through the use of integrated biomarkers in cardiocerebrovascular diseases in order to comply with regulatory and evidence-based medicine issues in the development of clinical trials.*

### Conclusions

#### WHAT'S NEXT

## GENERAL INFORMATION

### Date

The Course will start on Thursday, October 27, 2005 at 2.00 p.m. and will end on Saturday, October 29, 2005 in the afternoon.

### Venue

Hotel de la Paix (4 stars)  
Via Cattori, 18 - 6900 Lugano, Switzerland.  
The hotel is situated at walking distance from the center of Lugano and has a nice view of the beautiful lake and surrounding mountains.

### Scientific and Organizing Secretariat

Fondazione Giovanni Lorenzini  
Medical Science Foundation  
Via A. Appiani, 7 - 20121 Milan, Italy  
Phone: +39 02 29006267  
Fax: +39 02 29007018  
Email: [biomarkers@lorenzinifoundation.org](mailto:biomarkers@lorenzinifoundation.org)

**Maximum number of participants: 150**

### Cancellation

In case of cancellation, provided that written notice reaches Fondazione Giovanni Lorenzini no later than September 15, 2005 the registration and hotel accommodation fee will be refunded, less 60% administration charge. Regretfully written cancellations received after September 15, 2005 will not entitle the registrant to any refund; however, these registrants will receive their Course material by mail after the meeting. Refunds will be made after the Course.

### Official Language

The official language of the Course will be English; no simultaneous translation will be provided.

### Certificate of Attendance

Certificate of Attendance will be given to the participants attending all the sessions of the Course.

REGISTRATION AND HOTEL ACCOMMODATION FEE	Before Sept. 15, 2005	After Sept. 15, 2005
Participants	€ 1.400,00	€ 1.700,00
Regulatory Agencies Officers	€ 900,00	€ 1.000,00
Industry	€ 2.200,00	€ 2.500,00

### Registration and Hotel Accommodation Fee

Registration and hotel accommodation (full board) fee includes:

- participation in the Course
- scientific documentation
- lunches (Friday and Saturday)
- coffee breaks
- dinners (Thursday, Friday and Saturday)
- three nights accommodation in a room in single use at the Hotel de la Paix or in nearby hotels (4 stars) - Thursday, Friday, and Saturday nights on a first come - first served basis.

The reservation of the room will be done by Fondazione Giovanni Lorenzini.

### CME Credits

CME Credits for the International Course will be requested from EACCME (Accreditation Council for Continuing Medical Education) for European and US participants, and from the Italian Ministry of Health for Italian participants. Detailed information will be given at the Course.

### Posters

A limited number of posters on topics of specific interest will be accepted. Interested participants must contact the Scientific and Organizing Secretariat for further information, by September 15, 2005.

### Internet

The Home Page for the Course is located at: <http://www.lorenzinifoundation.org/biomarkers2005.html>

1<sup>st</sup> International Course  
**INTEGRATED BIOMARKERS**  
Lugano (Switzerland), October 27-29, 2005

**REGISTRATION AND HOTEL ACCOMMODATION FORM**

**Only one participant per form**

Please type or use block letters

Prof.  Dr.  Mr.  Mrs.  Ms.

Family Name \_\_\_\_\_

Given Name(s) \_\_\_\_\_

Name of Institution \_\_\_\_\_

Street \_\_\_\_\_

Town \_\_\_\_\_

Country \_\_\_\_\_ Postal Code \_\_\_\_\_

Phone No. \_\_\_\_\_ Fax No. \_\_\_\_\_

E-mail \_\_\_\_\_

REGISTRATION AND HOTEL ACCOMMODATION FEE	Before Sept. 15, 2005	After Sept. 15, 2005	Number of persons
Participants	€ 1.400,00	€ 1.700,00	1
Regulatory Agencies Officers	€ 900,00	€ 1.000,00	1
Industry	€ 2.200,00	€ 2.500,00	1

Registration and Hotel Accommodation Fee of € \_\_\_\_\_

I request the following reservations:

- Room in single use with bath/shower  
 Room in double use with bath/shower

Date of arrival \_\_\_\_\_

Date of departure \_\_\_\_\_

**Notes:**

- The cost of an extra night for a room in single use is about € 158 per night.
- The cost of an extra night for a room in double use is about € 203 per night.
- The difference between the room in single use and the room in double use is about € 45 per night.

**These extra costs will be charged directly to the participants by the hotel.**

